Invizius Limited

Company description

Invizius wants to improve outcomes for patients on dialysis, and other extra-corporeal treatments Extra-corporeal treatments like dialysis, and cardiopulmonary bypass, involve the circulation of the patient's blood supply through a machine. The patient's immune system treats the machine as a large, unwanted foreign body; the resulting inflammatory response contributes to a range of serious complications. Despite significant improvements in the quality and efficacy of hemodialysis therapy in recent years, cardiovascular disease (CVD) remains the leading cause of death for dialysis patients. Today, almost half of all dialysis patients die from cardiovascular complications, and life expectancy on dialysis is just one-third of normal. Cardiopulmonary bypass maintains blood circulation and oxygenation during open heart surgery, but drives up patients' risk of respiratory, hemotological and neurological complications. With its proprietary H-Guard™ biotechnology (based on our research into a bacterial peptide that modulates complement activation), Invizius is addressing the side effects of dialysis and other extra-corporeal treatments.

Invizius develops medical technology, called The H-Guard Priming Solution, that aims to eradicate side effects when conducting hemodialysis.

Project impact

Invizius has recently secured seed funding totalling nearly £3 from a consortium including Mercia Asset Management. Invizius, is now fully spun out and located in BioCity Glasgow with a team of 6. It is developing biocompatible medical devices such as dialysers coated with a functionally augmented form of FH (anchored by PspCN). It was named in 2018 as one of the 15 "Fierce Med Tech" companies, predicted to become one of the most important new companies in the industry.